AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2020
Feb 10, 2020
33422_dirs_2020-02-10_6b26c482-f23d-46e3-8a5a-5dd1665da574.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2020-02-09
Reporting Person: LEWIS JOEL (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-09 | Common Stock | M | 8000 | $2.39 | Acquired | 107104 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-09 | Stock option (right to buy) | $2.39 | M | 8000 | Disposed | 2027-12-14 | Common Stock (62250) | Direct |
Footnotes
F1: These options were issued pursuant to Galectin Therapeutics Inc.'s Amended and Restated 2009 Incentive Compensation Plan.
F2: The options became fully vested on December 14, 2018.
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21